HUTCHMED (China) HMDCF
NASDAQ HMDCF
$2.16 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

HUTCHMED (China) (HMDCF) Cash from Investing Activities (2018 - 2021)

HUTCHMED (China)'s (HMDCF) quarterly Cash from Investing Activities came in at -$315.9 million in Q2 2021, down 665.3% year-over-year from $55.9 million in Q2 2020, and down 297.41% quarter-over-quarter from $160.0 million in Q1 2021.

Analysis

HUTCHMED (China) (HMDCF) Cash from Investing Activities (2018 - 2021) Analysis & Trends

HUTCHMED (China) (HMDCF) has reported Cash from Investing Activities for 4 consecutive years, with -$315.9 million the latest figure, recorded in Q2 2021.

  • On a quarterly basis, Cash from Investing Activities fell 665.3% year-over-year to -$315.9 million in Q2 2021; TTM through Jun 2021 was -$295.0 million, a 281.98% decrease from a year earlier, with the FY2025 full-year figure at -$29.4 million, up 69.38% from the prior year.
  • Cash from Investing Activities was -$315.9 million for Q2 2021 at HUTCHMED (China), down from $160.0 million in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $160.0 million in Q1 2021 and troughed at -$315.9 million in Q2 2021.
  • A 4-year average of -$11.0 million and a median of $19.0 million in 2019 frame the typical range for Cash from Investing Activities.
  • Across the five-year window, Cash from Investing Activities jumped 299.29% in 2019 and plunged 665.3% in 2021, its largest moves.
  • Over 4 years, Cash from Investing Activities stood at -$15.3 million in 2018, then surged by 193.2% to $14.2 million in 2019, then slumped by 390.3% to -$41.3 million in 2020, then sank by 665.3% to -$315.9 million in 2021.
  • The last three Cash from Investing Activities figures came in at -$315.9 million (Q2 2021), $160.0 million (Q1 2021), and -$41.3 million (Q2 2020), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Amgen 211.37 Bn 197.38 Bn 7.24 Bn -569.00 Mn
2 Gilead Sciences 181.12 Bn 177.94 Bn 6.22 Bn -10.35 Bn
3 Vertex Pharmaceuticals 132.11 Bn 124.26 Bn 2.84 Bn -45.80 Mn
4 Regeneron Pharmaceuticals 82.51 Bn 74.52 Bn 3.93 Bn -92.70 Mn
5 Argenx Se 61.69 Bn 56.50 Bn 1.37 Bn -
6 Moderna 54.62 Bn 49.48 Bn 52.00 Mn 329.00 Mn
7 Alnylam Pharmaceuticals 34.14 Bn 30.84 Bn 992.69 Mn -363.46 Mn
8 Biogen 31.29 Bn 30.01 Bn 1.96 Bn -3.84 Bn
9 Roivant Sciences 30.09 Bn 30.09 Bn 1.16 Mn 281.26 Mn
10 HUTCHMED (China) 376.85 Mn 391.04 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2021 -315.92 Mn
Mar 31, 2021 160.04 Mn
Jun 30, 2020 -41.28 Mn
Mar 31, 2020 -97.84 Mn
Dec 31, 2019 14.22 Mn
Sep 30, 2019 47.67 Mn
Jun 30, 2019 23.76 Mn
Mar 31, 2019 33.38 Mn
Dec 31, 2018 -15.26 Mn
Sep 30, 2018 43.22 Mn
Jun 30, 2018 -11.92 Mn
Mar 31, 2018 27.71 Mn